Pembrolizumab +/- Zanzalintinib in 1st line tx of PD-L1+ Head and Neck cancer

A Phase 2/3, randomized, double-blind, controlled study of Zanzalintinib (XL092) in combination with pembrolizumab vs pembrolizumab in the first-line treatment of subjects with PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma

Disease Types: Head and Neck

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 2/3, randomized, double-blind, controlled study of Zanzalintinib (XL092) in combination with pembrolizumab vs pembrolizumab in the first-line treatment of subjects with PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma

For More Information:

https://clinicaltrials.gov/study/NCT06082167?term=PHASE%202%2F3,%20RANDOMIZED,%20DOUBLE-BLIND,%20CONTROLLED%20STUDY%20OF%20ZANZALINTINIB%20(XL092)%20IN%20COMBINATION%20WITH%20PEMBROLIZUMAB%20VS%20PEMBROLIZUMAB%20IN%20THE%20FIRST-LINE%20TREATMENT%20OF%20SUBJECTS%20WITH%20PD-L1%20POSITIVE%20RECURRENT%20OR%20METASTATIC%20HEAD%20AND%20NECK%20SQUAMOUS%20CELL%20CARCINOMA&rank=1